BREAST CANCER

Magtrace and Sentimag Magnetic Localization System, which uses magnetic detection to identify sentinel lymph nodes for surgical removal in women undergoing mastectomy for breast cancer, has gained approval from the FDA.

A biologics license application for sacituzumab govitecan has been granted a priority review by the FDA for the treatment of patients with metastatic triple-negative breast cancer following at least 2 prior therapies for metastatic disease, Immunomedics, the manufacturer of the antibody-drug conjugate, has announced.

Upfront ribociclib (Kisqali) has been granted approval by the FDA for use in combination with an aromatase inhibitor (AI) for the treatment of pre/perimenopausal or postmenopausal women with HR-positive/HER2-negative advanced or metastatic breast cancer. Additionally, ribociclib was approved in combination with fulvestrant for postmenopausal women with HR-positive/HER2-negative advanced or metastatic breast cancer.

General Cancer

Breast Cancer

In patients with metastatic or unresectable locally advanced triple-negative breast cancer, frontline treatment with atezolizumab (Tecentriq) plus nab-paclitaxel (Abraxane) significantly reduced the risk of disease progression or death compared with nab-paclitaxel, according to topline results from the phase III IMpassion130 study. 

Overall survival was not improved with the combination of palbociclib and fulvestrant compared with fulvestrant and placebo in the phase III PALOMA-3 trial for patients with HR-positive, HER2-negative metastatic breast cancer who received prior endocrine therapy, according to Pfizer, the developer of the CDK4/6 inhibitor.